Patients With Neuromyelitis Optica at Increased Risk for Fracture
Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.
Neuromyelitis Optica
Satralizumab Can Delay and Reduce Neuromyelitis Optica Spectrum Disorder Relapse Rate
Satralizumab monotherapy may reduce the risk for neuromyelitis optics spectrum disorder relapse, and has a favorable safety profile.
COVID-19 and Neuromyelitis Optica Disorder: A Need for Guidance-Based Management
Little guidance has been issued on how to manage patients with COVID-19 and coexisting neurological disorders.
Inebilizumab Shows Promise in Neuromyelitis Optica Spectrum Disorder
Inebilizumab is superior to placebo in reducing the risk for a neuromyelitis optica spectrum disorder attack.
FDA to Review Satralizumab for Neuromyelitis Optica Spectrum Disorder
The FDA has accepted the Biologics License Application (BLA) for satralizumab (Genentech) for the treatment of neuromyelitis optica spectrum disorder.
Immunosuppressive Therapy Prior to Pregnancy Not Associated With Negative Long-Term Outcomes in NMOSD
The use of immunosuppressive therapy (IST) prior to pregnancy in women with neuromyelitis optica spectrum disorder (NMOSD) is not associated with negative long-term outcomes.
FDA to Review Inebilizumab for Neuromyelitis Optica Spectrum Disorder
The Food and Drug Administration has accepted for review the Biologics License Application for inebilizumab for the treatment of patients with neuromyelitis optica spectrum disorder.
First Treatment for Neuromyelitis Optica Spectrum Disorder Approved
The FDA has approved Soliris (eculizumab; Alexion Pharmaceuticals, Inc) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Eculizumab Lowers Relapse Risk in Neuromyelitis Optica Spectrum Disorder
Long-term effect of eculizumab in patients with neuromyelitis optica spectrum disorder warrants further study, since there was no significant between-group difference in measures of disability progression.
Race May Affect Phenotype, Age of Onset, and Severity of Neuromyelitis Optica Spectrum Disorder
Investigators analyzed racial differences in the clinical features of neuromyelitis optica spectrum disorder.
-
Loading...
-
Loading...
Next post in General Neurology
